Gram Research analysis shows that a new PET scan using a gallium-68 labeled tracer can detect and measure liver scarring from MASH by targeting PDGFRβ, a protein on scar-forming cells. In preclinical studies with mice and human tissue samples, the scan signal increased with disease severity and accurately reflected the amount of liver damage present. While this early-stage research is not yet ready for patient use, it demonstrates PDGFRβ as a promising imaging biomarker that could eventually replace invasive liver biopsies for assessing MASH severity.
Scientists have developed a new type of medical scan that can detect liver damage from a condition called MASH (metabolic dysfunction-associated steatohepatitis) before it becomes severe. The scan uses a special tracer that highlights specific cells in the liver that cause scarring. In tests with mice and human liver samples, the scan accurately showed how much damage was present. This breakthrough could help doctors catch liver disease earlier and monitor how well treatments are working, potentially changing how we diagnose and treat this increasingly common liver condition.
Key Statistics
A preclinical research study published in Biochemical Pharmacology in 2026 found that a PDGFRβ-targeted PET scan successfully detected progressive liver scarring in both diet-induced mouse models of MASH and human liver tissue samples, with scan signal intensity correlating directly with fibrosis severity.
According to research reviewed by Gram, PDGFRβ expression and radioactive probe binding in human MASH specimens increased with pathological severity and correlated with fibrosis-associated markers, suggesting the scan could quantitatively grade disease progression.
The study demonstrated that the proportion of activated hepatic stellate cells (scar-forming cells) expressing PDGFRβ increased markedly in diseased livers compared to healthy tissue, providing a cellular basis for using this protein as an imaging target.
The Quick Take
- What they studied: Whether a new type of PET scan could detect and measure liver scarring caused by MASH, a fatty liver disease linked to obesity and metabolic problems.
- Who participated: The research used mice with diet-induced liver disease and human liver tissue samples from patients with MASH. No human patients were scanned in this study.
- Key finding: The new scan successfully detected liver scarring in both mouse models and human tissue samples, with the scan signal increasing as liver damage got worse.
- What it means for you: This research is early-stage and not yet available for patient use. If further testing succeeds, it could eventually offer doctors a better way to detect liver damage without needing a biopsy. However, more clinical trials are needed before this becomes a standard medical test.
The Research Details
Scientists created a special radioactive tracer—a tiny molecule tagged with gallium-68 that targets PDGFRβ, a protein found on scar-forming cells in the liver. They tested this tracer using PET imaging (a type of scan that shows where radioactive molecules go in the body) in two different mouse models of liver disease. The mice were fed special diets that cause fatty liver disease similar to human MASH. The researchers then compared the scan results with actual tissue samples, looking at how much scarring was present and how much of the target protein was expressed.
After testing in mice, the team validated their findings using human liver tissue samples from MASH patients. They used multiple techniques including imaging, microscopy, and genetic analysis to confirm that the tracer specifically bound to the scar-forming cells and that the signal correlated with disease severity.
Current methods for detecting liver scarring either require a liver biopsy (an invasive procedure with risks) or use indirect blood tests that don’t directly measure the cells causing scarring. This new approach could provide a non-invasive way to directly visualize and measure the specific cells driving liver damage, potentially allowing earlier detection and better monitoring of disease progression.
This is a well-designed preclinical study that used multiple complementary techniques to validate findings. The use of two different mouse models and human tissue samples strengthens confidence in the results. However, this is early-stage research conducted in laboratory and animal settings—human clinical trials are still needed to prove the scan works safely and effectively in actual patients.
What the Results Show
Both mouse models developed progressive liver scarring when fed special diets, and this scarring was accompanied by increasing amounts of PDGFRβ protein in the liver. The new PET scan successfully detected this protein, with scan signals increasing as liver damage worsened. The strength of the scan signal correlated directly with the amount of scarring seen under the microscope and with the level of scar-related genes being expressed in the tissue.
When the researchers examined human MASH liver samples, they found the same pattern: PDGFRβ expression increased with disease severity, and the radioactive tracer bound specifically to these scar-forming cells. The amount of tracer binding matched the degree of fibrosis (scarring) and other markers of liver damage.
The imaging measurements (quantified using standard PET analysis methods) accurately reflected the biological severity of the disease in both animal models and human tissue. This suggests the scan could potentially be used to grade how severe someone’s liver disease is without needing a biopsy.
The researchers confirmed that PDGFRβ is specifically located on activated hepatic stellate cells—the primary cell type responsible for creating liver scarring. The proportion of these scar-forming cells increased markedly as disease progressed. Autoradiography (a technique that shows exactly where the radioactive tracer binds in tissue samples) confirmed that the tracer specifically targeted these cells and didn’t bind non-specifically to other liver tissue.
Previous research has identified PDGFRβ as a marker of liver scarring, but this is the first study to develop and test a PET imaging probe targeting this protein. This approach is more direct than current non-invasive methods (blood tests) that measure indirect markers of liver damage. The findings support PDGFRβ as a superior imaging biomarker compared to existing approaches for assessing active fibrogenesis in MASH.
This research was conducted in laboratory animals and human tissue samples, not in living patients. The study doesn’t include safety data or information about how the scan would perform in actual clinical use. The sample size of human tissue samples is not specified in the abstract. Before this scan could be used in hospitals, researchers must conduct human clinical trials to confirm it’s safe, effective, and provides information that helps doctors make better treatment decisions. The long-term stability and optimal dosing of the radioactive tracer in humans also remains unknown.
The Bottom Line
This research is not yet ready for clinical use. Patients with MASH should continue following current medical guidance: maintaining a healthy weight, managing metabolic conditions like diabetes, and working with their doctors on liver health monitoring. Healthcare providers should monitor this research as it progresses toward human trials, as it may eventually offer a better diagnostic tool. Confidence level: This is early-stage research; recommendations are for future clinical application only.
This research is most relevant to: people with MASH or fatty liver disease, hepatologists (liver specialists), radiologists, and pharmaceutical companies developing MASH treatments. Patients with metabolic syndrome, obesity, or type 2 diabetes should be aware this research may eventually improve how their liver health is monitored. This study should not change current medical practice until human clinical trials are completed.
This is preclinical research. If development proceeds smoothly, human safety studies might begin in 2-3 years, with clinical efficacy trials potentially following 3-5 years after that. Realistic timeline for clinical availability: 5-10 years minimum, assuming successful progression through all trial phases.
Frequently Asked Questions
Can this new liver scan replace a liver biopsy?
Not yet. This is early-stage research in animals and tissue samples. Before the scan could replace biopsies, it must pass human clinical trials proving it’s safe and provides information doctors need. This process typically takes 5-10 years.
When will this liver imaging scan be available to patients?
This technology is not yet available for clinical use. Researchers must first conduct human safety trials, then efficacy trials. If development proceeds successfully, realistic timeline for clinical availability is 5-10 years minimum.
What is PDGFRβ and why does it matter for liver disease?
PDGFRβ is a protein found on hepatic stellate cells, the primary cells responsible for creating liver scarring in MASH. By targeting this protein with imaging, doctors could directly visualize which patients have active scar formation and how severe it is.
Does this scan work better than current liver disease tests?
This research suggests it could be more direct than current blood tests, which measure indirect markers of liver damage. However, this hasn’t been proven in human patients yet. Clinical trials are needed to compare it with existing diagnostic methods.
What should people with fatty liver disease do now?
Continue current medical recommendations: maintain healthy weight, manage metabolic conditions like diabetes, limit alcohol, and work with your doctor on liver health monitoring. This research may eventually improve diagnosis, but current treatments and lifestyle changes remain the standard approach.
Want to Apply This Research?
- Once this scan becomes available clinically, users could track liver health metrics over time: record dates of liver imaging scans, PDGFRβ levels if reported, fibrosis stage, and correlate with lifestyle factors (diet quality, exercise, weight changes) to see what interventions help slow progression.
- Users at risk for MASH could use the app to monitor modifiable risk factors: track daily steps, log meals to monitor calorie and sugar intake, record weight weekly, and monitor metabolic markers (blood sugar, cholesterol). When this scan becomes available, users could set goals to improve these factors before their next imaging assessment.
- Implement a quarterly check-in system where users review their metabolic health metrics and lifestyle changes. Create alerts for medical appointments and imaging scans. Build a dashboard showing trends in weight, activity, and dietary choices alongside any available liver health markers, helping users see connections between their behaviors and liver health outcomes.
This research describes early-stage preclinical findings in animal models and human tissue samples. The imaging probe described is not approved for human use and is not available clinically. This article is for educational purposes only and should not be interpreted as medical advice. Individuals with liver disease should consult their healthcare provider about appropriate diagnostic and treatment options. Any future clinical use of this technology would require regulatory approval and clinical trial validation. The findings presented here do not change current standard-of-care recommendations for MASH diagnosis and management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.